
|Videos|October 5, 2022
Neoadjuvant Chemotherapy as Standard-of-Care for Muscle-Invasive Urothelial Carcinoma
Srikala Sridhar, MD, MSc, FRCPC, explains the importance of neoadjuvant cisplatin-based chemotherapy and why bladder-sparing treatments should be considered for all patient populations.
Advertisement
Episodes in this series

Advertisement
Related to this article

UroGen submitted an NDA for UGN-103 in recurrent NMIBC, T-DXd improved PFS in first-line HER2-mutant lung cancer, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
European Commission Approves T-DXd Plus Pertuzumab for First-Line HER2+ Metastatic Breast Cancer
2
Dr Huffman on the Mechanism of Action of INCB161734 in KRAS G12D–Mutated Metastatic Pancreatic Cancer
3
TP53 Status and Treatment Toxicity Burden Guide Sequencing in EGFR-Mutated NSCLC
4
FDA Grants Fast Track Designation to MT027 for Recurrent Glioblastoma
5



